Genomes and Genes
Summary: Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism.
Publications153 found, 100 shown here
- Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescentsHelmut Niederhofer
Christian Doppler Clinic, A 5020, Salzburg, Austria
Drug Alcohol Rev 22:295-7. 2003..In some cases, disulfiram may be an effective and well-tolerated pharmacological adjunct to psychosocial and behavioural treatment programmes for treatment of adolescent alcohol-dependent patients...
- Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessmentBarbara J Mason
Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA
Eur Neuropsychopharmacol 13:469-75. 2003..The safety of the two drugs in combination has been supported by two independent double-blind studies, and combination treatment may offer an advantage for some patients...
- Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic reviewCarmen Bouza
Agency for Health Technology Assessment, Madrid, Spain
Addiction 99:811-28. 2004..To ascertain the efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence...
- Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine β-hydroxylaseJason P Schroeder
Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA
Neuropsychopharmacology 35:2440-9. 2010..Our results suggest that disulfiram's efficacy in the treatment of cocaine addiction is associated with the inhibition of DBH and interference with the ability of environmental stimuli to trigger relapse...
- The status of disulfiram: a half of a century laterJesse J Suh
Treatment Research Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 26:290-302. 2006..Preliminary evidence also suggests that disulfiram treatment could be a viable treatment for cocaine dependence because it was shown to reduce cocaine use among nonalcoholic, cocaine-dependent patients...
- The effectiveness of continuing group psychotherapy for outpatients with alcohol dependence: 77-month outcomesJee Wook Kim
Department of Neuropsychiatry, Hangang Sacred Heart Hospital, Hallym University, Seoul, Korea
Alcohol Clin Exp Res 36:686-92. 2012..On that basis, a long-term comparative trial was performed with the main objective of evaluating the effectiveness of continuing group PT for outpatients with AD...
- Medications for treating alcohol dependenceSteven H Williams
Psychology Service, Veterans Affairs Medical Center, Lebanon, Pennsylvania 17042, USA
Am Fam Physician 72:1775-80. 2005..S. Food and Drug Administration for this indication, the anticonvulsant topiramate and several serotonergic agents (e.g., fluoxetine, ondansetron) have been shown in recent studies to increase abstinence rates and decrease drinking...
- Pharmacotherapy of alcohol dependence: a review of the clinical dataKarl Mann
Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany
CNS Drugs 18:485-504. 2004..Pharmacotherapy should be used in association with appropriate psychosocial support and specific treatment provided for any underlying psychiatric comorbidities...
- A critical review of pharmacoeconomic studies of acamprosateFlavio Poldrugo
Office for Research and Innovative Projects on Alcohol, Other Addictions and Mental Health, Department of Psychiatry, University of Trieste, Via De Pastrovich 5 A, 34126 TRIESTE, Italy
Alcohol Alcohol 40:422-30. 2005..This review assessed the published data on the cost-effectiveness of acamprosate for the treatment of alcohol dependence...
- Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1George A Kenna
Center for Alcohol and Addiction Studies, Brown University, Providence, RI, USA
Am J Health Syst Pharm 61:2272-9. 2004..The neurobiological basis of alcohol dependence, established pharmacotherapies for alcohol dependence, pharmacotherapies under investigation, and obstacles to treatment are discussed...
- Disulfiram impairs the development of behavioural sensitization to the stimulant effect of ethanolAndrezza Kyunmi Kim
Departamento de Psicobiologia Universidade Federal de São Paulo UNIFESP, Rua Napoleao de Barros 925, Sao Paulo, Sao Paulo, Brazil
Behav Brain Res 207:441-6. 2010..This study sought to analyze the influence of disulfiram on the development of behavioural sensitization to the stimulant effect of ethanol...
- An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependenceAvinash De Sousa
Get Well Clinic and Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, Maharashtra State, India
Alcohol Alcohol 40:545-8. 2005..To compare the efficacy of acamprosate (ACP) and disulfiram (DSF) for preventing alcoholic relapse in routine clinical practice...
- [Pharmacology of disulfiram - an update]J Mutschler
Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut fur Seelische Gesundheit, Mannheim
Fortschr Neurol Psychiatr 76:225-31. 2008..As an example we demonstrate a case, in which an acute neurological deficit was misjudged as a side effect of Disulfiram. Furthermore, the potential of Disulfiram as a promising treatment in addiction medicine will be discussed...
- New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependenceFalk Kiefer
University of Heidelberg, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, CIMH, J5, D 68159 Mannheim, Germany
Eur J Pharmacol 526:163-71. 2005..New compounds are under investigation. This review discusses the neurobiological basis of alcohol addiction, pharmacological targets for relapse prevention treatment and pre-clinical and clinical results with the most promising drugs...
- Pharmacological approaches to the management of alcohol addictionG Addolorato
Istituto di Medicina Interna, Universita Cattolica del Sacro Cuore, Roma
Eur Rev Med Pharmacol Sci 6:89-97. 2002..However, pharmacotherapy should not be considered as the only form of treatment but as an integrated part of a multimodal approach including psychological and social support...
- Disulfiram treatment for alcoholism in severe mental illnessKim T Mueser
Department of Psychiatry, Dartmouth Medical School, Concord, NH, USA
Am J Addict 12:242-52. 2003..The results suggest disulfiram may be a useful adjunctive treatment for alcoholism in patients with severe mental illness and that controlled research is needed to evaluate its effects in this population...
- A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependenceAlan de Sousa
Get Well Clinic and Nursing Home, 33rd Road, Off Linking Road, Bandra, Mumbai 400050, India
Alcohol Alcohol 39:528-31. 2004..To compare the efficacy of naltrexone and disulfiram in preventing an alcoholic relapse in routine clinical practice in an Indian metropolis...
- New pharmacotherapies for alcohol dependenceRobert Graham
St Vincent s Hospital, Sydney, NSW, Australia
Med J Aust 177:103-7. 2002..Adjunctive psychosocial treatment with close follow-up is required for acamprosate and recommended for naltrexone. As yet, no studies have reported a reduction in mortality following the use of any pharmacotherapy for alcohol dependence...
- Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patientsAlexander Diehl
Department of Psychiatry, Klinikum Braunschweig, Braunschweig, Germany
Alcohol Alcohol 45:271-7. 2010..To compare the long-term effectiveness of acamprosate (ACP) and disulfiram (DSF) in the treatment of alcohol dependence and their effectiveness in regard to patient characteristics, within a naturalistic outpatient treatment setting...
- Alcohol dependence: analysis of factors associated with retention of patients in outpatient treatmentMárcia Fonsi Elbreder
Alcohol and Drugs Research Unit Uniad, Rua Botucatu 394 Vila Clementino CEP 04023 061, Sao Paulo SP, Brazil
Alcohol Alcohol 46:74-6. 2011..To identify factors associated with retention in treatment of alcohol-dependent individuals and to compare treatment retention between men and women...
- Supervised disulfiram as adjunct to psychotherapy in alcoholism treatmentHenning Krampe
Department of Anaesthesiology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, Germany
Curr Pharm Des 16:2076-90. 2010....
- Safety issues concerning the use of disulfiram in treating alcohol dependenceJ Chick
Department of Psychiatry, University of Edinburgh, Scotland
Drug Saf 20:427-35. 1999..Disulfiram can be viewed as a drug with a moderate record of adverse effects. Alcohol dependence, for which it can be a helpful treatment, is associated with a high morbidity and mortality...
- The use of disulfiram for alcohol-dependent patients and duration of outpatient treatmentMárcia Fonsi Elbreder
Department of Psychiatry, Federal University of Sao Paulo UNIFESP, Sao Paulo, Brazil
Eur Arch Psychiatry Clin Neurosci 260:191-5. 2010..Although disulfiram is an old medication, it seems that this drug can be useful for keeping alcohol-dependent patients under outpatient treatment...
- Paradigm to test a drug-induced aversion to ethanolE Garver
Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Alcohol Alcohol 35:435-8. 2000..This model should be of value in the testing of new agents that reduce aldehyde dehydrogenase levels for prolonged periods for their potential as an aversive treatment in alcoholism...
- [The role of the glutamatergic system in the pathogenesis and treatment of alcohol dependence]Karina Łukasik
Zakład Farmakodynamiki Uniwersytetu Medycznego w Łodzi, Łódź
Postepy Hig Med Dosw (Online) 64:534-43. 2010..There are promising preclinical results of groups I and II metabotropic receptor antagonists. However, further studies are necessary to elucidate precisely their role in alcohol dependence...
- Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patientsL Annemans
Vrije Universiteit Brussel, Brussels, Belgium
Eur Addict Res 6:71-8. 2000..A global anticipated net saving of 70 million BEF (1.74 million Euro) over 2 years was estimated for the Belgian health insurance...
- Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trialRaymond F Anton
Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston 29425, USA
JAMA 295:2003-17. 2006..Alcohol dependence treatment may include medications, behavioral therapies, or both. It is unknown how combining these treatments may impact their effectiveness, especially in the context of primary care and other nonspecialty settings...
- Treatment of alcohol-dependent outpatients with acamprosate: a clinical reviewB J Mason
Department of Psychiatry and Behavioral Sciences, University of Miami/JMH Medical Center, Fla 33136, USA
J Clin Psychiatry 62:42-8. 2001..The drug's reliable effect on prolonging abstinence, in conjunction with an excellent safety profile, suggests that acamprosate may be useful for a broad range of patients with alcohol dependence...
- Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled studyKee Namkoong
Department of Psychiatry, Yonsei University College of Medicine, Seoul, South Korea
Alcohol Alcohol 38:135-41. 2003..A multi-centre, randomized, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and the safety of acamprosate over 8 weeks in Korean alcohol-dependent patients...
- Does disulfiram have a role in alcoholism treatment today?Richard K Fuller
Addiction 99:21-4. 2004
- Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patientsRoel Verheul
Department of Clinical Psychology, University of Amsterdam, Amsterdam, The Netherlands
Psychopharmacology (Berl) 178:167-73. 2005..However, acamprosate prevents lapses or relapses only in a minority of patients. An important question, therefore, is whether there is a specific subgroup of patients who respond particularly well to acamprosate...
- Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysisH R Kranzler
Alcohol Research Center, Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut, USA
Alcohol Clin Exp Res 25:1335-41. 2001..In the absence of studies that compare the effects of these medications, we used a meta-analytic approach to the literature to compare their efficacy in alcoholism treatment...
- Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trialFernando A Furieri
Vitória Municipal Addiction Treatment Center, Vitoria, Espirito Santo, Brazil
J Clin Psychiatry 68:1691-700. 2007..This study examined the efficacy of a 28-day gabapentin treatment in reducing alcohol consumption and craving...
- Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcomeHenning Krampe
Department of Psychiatry and Psychotherapy, Georg August University, and Max Planck Institute of Experimental Medicine, Goettingen, Germany
Alcohol Clin Exp Res 30:86-95. 2006..patients, participants of the Outpatient Longterm Intensive Therapy for Alcoholics (OLITA); (2) To investigate the role of supervised alcohol deterrents (AD) in relapse prevention and as an adjunct for maintenance of long-term abstinence.
- Combined therapy: what does acamprosate and naltrexone combination tell us?Falk Kiefer
Department of Psychiatry, University Hospital of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
Alcohol Alcohol 39:542-7. 2004..It remains to be answered whether data justify the combination of both drugs in clinical practice...
- Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled studyLeonid S Shpilenya
Narcological County Dispensary, Vasyleostrovsky District 4 th, Line V 0 2 3 2 5, St Petersburg, Russia
Alcohol Clin Exp Res 26:340-6. 2002..The present study was planned with the aim of investigating the effectiveness of metadoxine in the management of patients affected by acute ethanol intoxication...
- Metadoxine in the treatment of acute and chronic alcoholism: a reviewG Addolorato
Institute of Internal Medicine, Catholic University of Rome, Italy
Int J Immunopathol Pharmacol 16:207-14. 2003..In this review the preclinical and clinical results obtained using metadoxine in acute and chronic alcohol intoxication are reported...
- New pharmacological approaches for the treatment of alcoholismMichael Soyka
Private Hospital Meiringen, P O Box 612, CH 3860 Meiringen, Switzerland
Expert Opin Pharmacother 7:2341-53. 2006..Tricyclics have been found to be more effective than serotonin reuptake inhibitors in improving depressive symptoms in these patients...
- Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptionstFelice Nava
Department of Addiction Medicine, Drug Abuse Unit Ser T, Hospital of Castelfranco Veneto, Via Ospedale, 18, 31033 Castelfranco Veneto Treviso, Italy
J Psychoactive Drugs 38:211-7. 2006..The maximum effects were observed in GHB-treated patients. The results of the present study suggest that GHB might act both as anticraving and cellular protector agent...
- [The pharmacologic treatment of the alcohol dependence]Luís André Castro
Unidade de Pesquisa Clínica, Unidade de Pesquisa em Alcool e Drogas, Departamento de Psiquiatria, EMP UNIFESP, Brazil
Rev Bras Psiquiatr 26:S43-6. 2004..Ondansetron, has shown promise in the early-onset alcohol dependence but needs more extensive study. Topiramate (up to 300 mg per day) was more efficacious than placebo in the treatment of alcohol dependence...
- [Neurobiological mechanisms and pharmacological treatment options for alcohol craving]T Hillemacher
Psychiatrische und Psychotherapeutische Klinik, Universitatsklinikum Erlangen, Germany
Fortschr Neurol Psychiatr 75:26-32. 2007..Besides, there are several promising candidate substances. Current investigations focus on a differentiated pharmacotherapy of alcohol dependence, including psychological and genetic factors...
- Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disordersIsmene L Petrakis
Department of Psychiatry, Yale University, New Haven, Connecticut 06516, USA
Biol Psychiatry 57:1128-37. 2005..Disulfiram and naltrexone are approved by the Food and Drug Administration (FDA) for the treatment of alcoholism, but these agents have not been rigorously evaluated in dually diagnosed individuals...
- Trends in the adoption of medications for alcohol dependenceLori J Ducharme
Institute for Behavioral Research, University of Georgia, Athens, GA 30602 2401, USA
J Clin Psychopharmacol 26:S13-9. 2006..Preliminary data suggest that the early adoption of acamprosate is following a similar pattern. Recommendations for addressing challenges to the diffusion of pharmacotherapies for alcohol dependence are presented...
- Pharmacotherapy for alcohol dependence: anticraving medications for relapse preventionYoung Chul Jung
Department of Psychiatry, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul 120 752, Korea
Yonsei Med J 47:167-78. 2006..In addition, novel medications are being investigated to assess their efficacy in preventing relapse and increasing abstinence...
- Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholismFalk Kiefer
Department of Addictive Behaviour and Addiction Medicine, Central Institute of Mental Health CIMH, University of Heidelberg, J5, 68159 Mannheim, Germany
J Psychiatr Res 39:545-51. 2005..Moreover, there are hints for an interaction between pharmacological anti-craving treatment, plasma concentration of leptin, and abstinence duration...
- Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?Falk Kiefer
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany
Biol Psychiatry 60:74-6. 2006..We examined the relationship between efficacy of pharmacological anticraving treatment and HPA axis activity in the relapse prevention treatment of alcoholism...
- [Maintaining abstinence after alcohol detoxification]Philippe Batel
Traitement ambulatoire des maladies de l alcool, Hopital Beaujon, Clichy
Rev Prat 56:1100-6. 2006....
- Alcoholism and suicidal behavior: a clinical overviewL Sher
Division of Neuroscience, Department of Psychiatry, Columbia University, New York, NY 10032, USA
Acta Psychiatr Scand 113:13-22. 2006..The purpose of this paper was to provide a clinical review of the literature on the relation of alcoholism to suicidal behavior...
- Choosing the right medication for the treatment of alcoholismHelen M Pettinati
Department of Psychiatry, University of Pennsylvania, Treatment Research Center, 3900 Chestnut Street, Philadelphia, PA 19104 6178, USA
Curr Psychiatry Rep 8:383-8. 2006..This report reviews the latest innovations in pharmacotherapy for the treatment of alcohol dependence, focusing on FDA-approved medications presently available to the treatment community...
- Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practiceChristopher M Doran
School of Population Health, School of Economics, University of Queensland, Mayne Medical Building, Herston Road, Herston QLD 4006, Australia
Addict Behav 31:1947-58. 2006..To collect data on the behaviours associated with the prescription of pharmacotherapies (bupropion, acamprosate and naltrexone) for nicotine and alcohol dependence in Australian clinical practice...
- Pharmacotherapy of alcohol use disordersAlessandra Buonopane
Department of Psychiatry, School of Medicine, Yale University, New Haven, Connecticut, USA
Subst Use Misuse 40:2001-20, 2043-8. 2005..An overview of the serotonergic agents is also provided. Finally, future directions, including new medications and some clinical strategies that show promise but are not yet used extensively clinically, are mentioned...
- Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in IndiaDebasish Basu
Drug De addiction and Treatment Centre, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Am J Addict 14:381-95. 2005..Logistic regression analysis showed that both family/social support and acamprosate appeared to contribute modestly toward explaining the variance in short-term outcome...
- Pharmacological treatment of alcohol dependence: target symptoms and target mechanismsMarkus Heilig
National Institute on Alcohol Abuse and Alcoholism NIH DHHS, 10 Center Drive, 10 1E 5334 Bethesda, MD 20892 1610, United States
Pharmacol Ther 111:855-76. 2006..Once novel treatments are developed, the field faces a major challenge to assure their delivery to patients...
- Extended-release intramuscular naltrexone: a viewpoint by Henry R KranzlerHenry R Kranzler
University of Connecticut School of Medicine, Farmington, CT, USA
Drugs 66:1753-4. 2006
- The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disordersAron N Starosta
University of Pennsylvania, PA 19104, USA
J Psychiatr Pract 12:80-9. 2006..This paper describes these components and discusses how the empirical support for each component is linked to the enhancement of medication compliance and the improvement of treatment outcomes...
- Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?Sheila A Doggrell
School of Science, Faculty of Education, Health and Science, Charles Darwin University, Darwin, Northern Territory 0909, Australia
Expert Opin Pharmacother 7:2169-73. 2006..In COMBINE, this percentage was high in the group having medical management and placebo pills, and naltrexone or additional behavioural therapy only had modest additional effects...
- Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapyGerald F X Feeney
Alcohol and Drug Assessment Unit, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia
Alcohol Alcohol 41:321-7. 2006..To compare treatment outcomes amongst patients offered pharmacotherapy with either naltrexone or acamprosate used singly or in combination, in a 12-week outpatient cognitive behavioural therapy (CBT) programme for alcohol dependence...
- [Pharmacological relapse prevention in alcohol and tobacco dependence]A Diehl
Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut fur Seelische Gesundheit, J5, 68159, Mannheim, Germany
Internist (Berl) 48:79-84, 86-8. 2007..A specific application of these substances will optimise the outcome for alcohol and tobacco dependent patients...
- Preclinical and clinical pharmacology of alcohol dependenceSophie Tambour
Unité de Recherche en Psychologie Expérimentale et Neurosciences Cognitives URPENC, Universite de Liege, Boulevard du Rectorat 5 B32, B 4000 Liege, Belgium
Fundam Clin Pharmacol 21:9-28. 2007..These new drugs in the field of alcohol pharmacotherapy are also discussed, together with their mechanisms of action...
- From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gapChristopher W Shea
Fr Martin s Ashley, Havre de Grace, Maryland 21078, USA
South Med J 101:179-85. 2008..Pharmacotherapy represents a valuable component of treatment and should be combined with psychosocial and behavioral interventions to address the multifactorial nature of AD in individuals with this disease...
- AcamprosateBarbara J Mason
Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, Florida 33136, USA
Recent Dev Alcohol 16:203-15. 2003
- [Pharmacological review of alcoholic dependence treatment]Leandro Oural
Vertex 19:512-21. 2008..We will also refer to topiramate, which is being studied for this indication...
- Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?Kylie Richardson
Central Clinical School of Medicine, University of Sydney, NSW, Australia
Addiction 103:953-9. 2008..To explore the effect of acamprosate and naltrexone on craving and alcohol consumption in the treatment of alcohol dependence...
- The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trialsJames L Snyder
Penn State Harrisburg, Middletown, Pennsylvania 17057, USA
Am J Drug Alcohol Abuse 34:449-61. 2008..There was insufficient data available to ascertain the efficacy of naltrexone and acamprosate over prolonged periods of time, or the effectiveness of the medications relative to each other...
- A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexoneBarbara J Mason
Division of Substance Abuse, Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami, FL, USA
Neuropsychopharmacology 27:596-606. 2002..A complete absence of negative interactions on measures of safety and cognitive function supports the absence of a contraindication to co-administration of acamprosate and naltrexone in clinical practice...
- [Long-term treatment of alcohol dependance]Louis Philippe Fideli
Psychiatrie, CHU Louis Mourier, 178, rue des Renouillers, 92700 Colombes, France
Gastroenterol Clin Biol 26:B169-73. 2002
- Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorderIsmene L Petrakis
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA
Biol Psychiatry 60:777-83. 2006....
- Addiction medicine for the primary care physicianW H Yarborough
University of Oklahoma, College of Medicine, Tulsa Campus, Department of Internal Medicine, 4502 E. 41st Street, Tulsa, OK 74135-2512, USA
J Okla State Med Assoc 94:499-506. 2001..Finally a look at parity for addiction treatment with a discussion of the cost and the benefits to society are also outlined...
- Pharmacologic approaches to the management of alcoholismR F Anton
Alcohol Research Center, Medical University of South Carolina, Charleston 29425, USA
J Clin Psychiatry 62:11-7. 2001..This article will discuss animal and clinical studies of the opioid antagonists (primarily naltrexone), acamprosate, and disulfiram. The side effects and treatment recommendations for each drug will also be reviewed...
- Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatmentG Rubio
Psychiatric Service, 12 de Octubre University Hospital, Madrid, Spain
Alcohol Alcohol 36:419-25. 2001..There were non-significant trends for the naltrexone group to comply better with medication, to stay in the study longer, and to show greater improvement over baseline in serum GGT...
- Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trialsJ A Boening
Department of Psychiatry, Addiction Medicine, University of Wuerzburg, Germany
Alcohol Clin Exp Res 25:127S-131S. 2001..Wiesbeck; and (6) Methodology and behavioral therapy of the U.S. acamprosate study, by Barbara J. Mason...
- [Alcohol dependence: diagnosis and treatment]P Perney
Service d Addictologie, CHU Caremeau, 30029 Nimes Cedex 9, France
Rev Med Interne 29:297-304. 2008..5 million patients in France. A review about alcohol dependence is warranted, not only as prevalence of this disease is high, but also because of recent significant improvement in caring for these patients...
- Physicians' opinions about medications to treat alcoholismTami L Mark
Medstat, Washington, DC 20008, USA
Addiction 98:617-26. 2003..This paper examines physicians' opinions about and use of two alcoholism medications currently approved in the US--disulfiram and naltrexone--and one alcoholism medication--acamprosate--that might be approved...
- Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomesSusanne Rösner
IFT, Institut für Therapieforschung, Munich, Germany
J Psychopharmacol 22:11-23. 2008..Benefits in the treatment of alcohol dependence might be optimized by matching the efficacy profiles of specific antidipsotropics with the motivational status of alcohol-dependent patients...
- Recent advances in the pharmacotherapy of alcoholismHugh Myrick
Alcohol Research Center, Medical University of South Carolina Department of Psychiatry and Behavioral Sciences, 67 President Street, Charleston, SC 29425, USA
Curr Psychiatry Rep 6:332-8. 2004..Data on naltrexone, acamprosate, and topiramate will be highlighted. In addition, data concerning the use of serotonin reuptake inhibitors in subtypes of alcoholism and the use of combination pharmacotherapy will be reviewed...
- The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholicsWendy Ooteman
Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands
Eur Neuropsychopharmacol 17:558-66. 2007..It is hypothesized that naltrexone exerts its effects primarily on cue-induced craving and neuroendocrine cue reactivity, whereas acamprosate exerts its effect primarily on autonomic nervous system reactions to alcohol-related cues...
- Naltrexone and disulfiram in patients with alcohol dependence and current depressionIsmene Petrakis
Department of Psychiatry, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven Campus, West Haven, CT 06516, USA
J Clin Psychopharmacol 27:160-5. 2007..In particular, the effect of these medications on alcohol use outcomes and on specific psychiatric symptoms is still unknown in patients with the most common co-occurring disorder, major depression...
- Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspectiveMichael Soyka
Psychiatric Hospital, University of Munich, Munich, Germany
Am J Addict 12:S69-80. 2003..Some centers suggest naltrexone not only for patients aiming for abstinence but also for patients for whom continued drinking is a therapeutic possibility or a clinical inevitability...
- Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in SwitzerlandCaroline Buri
University Hospital of Psychiatry Bern, Bolligenstrasse 111, 3000 Bern 60, Switzerland
Alcohol Alcohol 42:333-9. 2007..There remains, however, a paucity of studies with sufficient external validity in which the effectiveness of pharmacotherapy in clinical practice is investigated. This study aimed to make a contribution to close this gap in research...
- Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependenceJohn Littleton
Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, KY 40546 0236, USA
Am J Addict 12:S3-11. 2003....
- [Drug therapy of alcohol dependence--a critical review]Mikko Salaspuro
Biomedicum Helsinki, Päihdelääketieteen tutkimusyksikkö PL 63, 00014 Helsingin yliopisto
Duodecim 119:2503-7. 2003
- Effect of the combination of naltrexone and acamprosate on alcohol intake in miceSung Gon Kim
Department of Psychiatry, School of Medicine, Pusan National University, Pusan, Korea
Psychiatry Clin Neurosci 58:30-6. 2004..When combined with naltrexone, acamprosate reduced alcohol consumption across both doses of naltrexone. This effect was sensitive to both dose and number of days of exposure to the naltrexone/acamprosate combination...
- Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokersLutz G Schmidt
Department of Psychiatry, Johannes Gutenberg University Mainz, Untere Zahlbacher Str 8, 55131 Mainz, Germany
Alcohol Alcohol 42:241-6. 2007..To assess the role of smoking on treatment outcome in quitting alcoholics on the background of the priming or coping hypothesis (Rohsenow et al., 1997)...
- Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexoneFalk Kiefer
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, University of Heidelberg, Germany
Addict Biol 13:124-9. 2008..It is discussed whether especially these subjects should be targeted for pharmacological relapse prevention treatment with naltrexone...
- Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone, and other pharmacological antagonists and intensive "immersion" methods of foreign language teachingColin Brewer
The Stapleford Centre, London, United Kingdom
Subst Abus 24:157-73. 2003..Supervised or depot naltrexone acts similarly in opiate dependence. We discuss the concept of antagonist-assisted abstinence...
- New therapies for alcohol dependence open options for office-based treatmentBridget M Kuehn
JAMA 298:2467-8. 2007
- A standardized kudzu extract (NPI-031) reduces alcohol consumption in nontreatment-seeking male heavy drinkersScott E Lukas
Behavioral Psychopharmacology Research Laboratory MIC, Mail Stop 319 McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA
Psychopharmacology (Berl) 226:65-73. 2013..The present study was conducted in nontreatment-seeking heavy drinkers to assess the safety and efficacy of 4 weeks of kudzu extract in an outpatient setting...
- The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded ratsRui Ting Wen
National Institute on Drug Dependence, Peking University, Beijing, China
Alcohol Clin Exp Res 36:2157-67. 2012..Thus, it was of interest to determine whether PDE4 was involved in the regulation of alcohol use and abuse...
- [Pharmacological features of naltrexone and its use in the treatment of alcohol dependence]Przemysław Bieńkowski
Zaklad Farmakologii i Fizjologii Ukladu Nerwowego IPiN w Warszawie Kierownik
Psychiatr Pol 47:117-26. 2013..The aim of the present article is to review the basic pharmacological features of naltrexone and its use in the treatment of alcohol dependence...
- New pharmacological treatment strategies for relapse preventionRainer Spanagel
Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Square J5, 68159 Mannheim, Germany
Curr Top Behav Neurosci 13:583-609. 2013..However, it will still be several years before the majority of the "treatment-seeking population" will benefit from those developments...
- Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapyMaziyar Amini
Department of Gastroenterology and Hepatology, Loma Linda University Medical Center, 11234 Anderson Street, 1556, Loma Linda, CA 92354, United States
World J Gastroenterol 16:4905-12. 2010....
- The effect of alcohol treatment on social costs of alcohol dependence: results from the COMBINE studyGary A Zarkin
RTI International, Research Triangle Park, NC 27709, USA
Med Care 48:396-401. 2010..Policy makers, patients, and nonalcohol-dependent individuals may be concerned not only with alcohol treatment costs but also with the effect of alcohol interventions on broader social costs and outcomes...
- Nursing research and alcohol problems: learning from recent history?Maurice Dongier
McGill University, Montreal, Quebec, Canada
Can J Nurs Res 35:13-22. 2003
- The anti-craving taurine derivative acamprosate: failure to extinguish morphine conditioned place preferenceM Foster Olive
Ernest Gallo Clinic and Research Center, Department of Neurology, University of California at San Francisco, California, USA
Adv Exp Med Biol 526:481-4. 2003
- New pharmacotherapies for alcohol dependence: are they being used and what do they cost?Christopher M Doran
Med J Aust 179:218. 2003
- Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brainM al Qatari
Pharmacology Group of Kings College, London, United Kingdom
Alcohol Clin Exp Res 25:1276-83. 2001..The results are, however, compatible with other inhibitory effects on NMDA receptor function...
- Acamprosate modulates alcohol-induced hippocampal NMDA receptors and brain microsomal Ca2+-ATPase but induces oxidative stress in ratAli Metehan Calişkan
Department of Physiciatry, Medical Faculty, Suleyman Demirel University, Isparta, Turkey
J Membr Biol 237:51-8. 2010..Oxidative stress has been proposed to explain the biological side effects of experimental alcohol intake. Acamprosate and alcohol-induced oxidative stress decreased brain antioxidant vitamins in the alcoholic rats...
- Potential neuroprotective effects of acamprosateGeorge F Koob
Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California, USA
Alcohol Clin Exp Res 26:586-92. 2002..Siggins; (3) Acamprosate and glutamate during ethanol withdrawal, by Philippe De Witte; (4) Clinical evidence of protective CNS effects of acamprosate in alcohol-dependent individuals, by Barbara J. Mason...
- Advances in the use of naltrexone: an integration of preclinical and clinical findingsSTEPHANIE S O'MALLEY
Yale University School of Medicine, New Haven, Connecticut 06519, USA
Recent Dev Alcohol 16:217-45. 2003..Ultimately, these lines for research promise to provide critical information that can be used to maximize the efficacy of naltrexone for treating alcoholism...
- OLITA: an alternative in the treatment of therapy-resistant chronic alcoholics. First evaluation of a new approachH Ehrenreich
Department of Psychiatry, Georg August University, Gottingen, Germany
Eur Arch Psychiatry Clin Neurosci 247:51-4. 1997....
- [Acute encephalopathy and polyneuropathy from disulfiram: toxicity and interactions]A Berger
Therapie 57:505-7. 2002
- Medication Development for Protracted Abstinence in AlcoholismBarbara Mason; Fiscal Year: 2009..abstract_text> ..
- MEDICATION DEVELOPMENT FOR PROTRACTED ABSTINENCE IN ALCOBarbara Mason; Fiscal Year: 2003..abstract_text> ..
- Pharmacological Treatment of Cannabis Withdrawal and DependenceBarbara J Mason; Fiscal Year: 2010..The development of vofopitant as a novel medication for CD may have major public health benefits and is highly significant for the mission of NIDA. ..
- Gabapentin Treatment of Cannabis DependenceBarbara J Mason; Fiscal Year: 2010....
- Mecamylamine for the Treatment of Alcohol DependenceIsmene Petrakis; Fiscal Year: 2009..We will also evaluate smoking use outcomes and use this study as a platform to conduct future studies. This is the first study conducted to evaluate mecamylamine as a potential pharmacotherapeutic agent for alcohol dependence. ..
- RESEARCH TRAINING FELLOWSHIP IN SUBSTANCE ABUSEIsmene Petrakis; Fiscal Year: 2007..At the conclusion of training, applicants will be well suited for independent careers in translational or intervention research in the field of addiction. ..
- Mecamylamine for the Treatment of Alcohol DependenceIsmene L Petrakis; Fiscal Year: 2010..We will also evaluate smoking use outcomes and use this study as a platform to conduct future studies. This is the first study conducted to evaluate mecamylamine as a potential pharmacotherapeutic agent for alcohol dependence. ..
- Translational Neuroscience Research in AlcoholismIsmene Petrakis; Fiscal Year: 2007..At the conclusion of training, applicants will be well suited for independent careers in translational research in the field of alcoholism. ..
- Computer-based Training in Cognitive Behavioral Therapy: Web-based delivery of CBKathleen M Carroll; Fiscal Year: 2011....
- Maximizing CBT's Efficacy with Medication & CMKathleen Carroll; Fiscal Year: 2009..Variables assessing theoretical mechanisms of action will be assessed monthly during treatment. ..
- Maximizing Effectiveness of Cognitive Behavior Therapy and Contingency ManagementKathleen Carroll; Fiscal Year: 2007..Study treatments will last 12 weeks. Primary outcomes will be percent days abstinent and results of urine toxicology screens. ..
- CLINICAL TRIALS NETWORK: NEW ENGLAND NODEKathleen Carroll; Fiscal Year: 2007....
- Computer-Based Training in Cognitve Behavioral TherapyKathleen Carroll; Fiscal Year: 2002..The patients' ability to demonstrate coping skills through a role-play evaluation will be a secondary outcome. A six-month follow-up will assess durability and/or delayed emergence of effects. ..
- Computer-Based Training in Cognitve Behavioral TherapyKathleen Carroll; Fiscal Year: 2007..abstract_text> ..
- PSYCHOTHERAPY OF SUBSTANCE USE DISORDERSKathleen Carroll; Fiscal Year: 2007..To maximize the effectiveness and durability of CM for abstinence, we will evaluate the benefit of integrating CM with skills training specifically designed to reduce drop-off of CM's benefits. ..
- Diffusion, Adoption, and Implementation of Pharmacotherapies in Alcohol TxAMANDA ABRAHAM; Fiscal Year: 2007..This information will be relevant to treatment providers, health researchers, and health policymakers as they seek to bridge the "research to practice gap" and improve access to quality treatment for persons suffering from alcoholism. ..
- GENETICS OF COCAINE DEPENDENCEHENRY RICHARD KRANZLER; Fiscal Year: 2010..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
- Matching 5-HT Genotypes to Serotonergic Medications for AlcoholismGEORGE KENNA; Fiscal Year: 2007....
- Matching 5-HT Genotypes to Serotonergic Medications for AlcoholismGEORGE KENNA; Fiscal Year: 2009....
- Matching 5-HT Genotypes to Serotonergic Medications for AlcoholismGEORGE ANTHONY KENNA; Fiscal Year: 2010....
- Sertraline Pharmacotherapy for Alcoholism SubtypesHenry Kranzler; Fiscal Year: 2007..abstract_text> ..
- GENETICS OF COCAINE DEPENDENCEHenry Kranzler; Fiscal Year: 2007..Knowledge of the gene variants will help to identify people at greatest risk of developing the disorder, thereby improving prevention efforts. ..
- Planning for a CTSA Application at the University of ConnecticutJudith Fifield; Fiscal Year: 2006..New resources committed to the CTR effort by the State of Connecticut and by UCONN will contribute to the achievement of these specific aims and should make possible the submission of a CTSA U54 application in late 2007. ..
- Novel Approaches to Alcoholism Pharmacotherapy and RiskHenry Kranzler; Fiscal Year: 2006..abstract_text> ..
- NALTREXONE AND COGNITIVE BEHAVIOR THERAPY OF ALCOHOLISMRaymond Anton; Fiscal Year: 1993....
- Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?Alan Green; Fiscal Year: 2009..Finding medications that may be able to limit cannabis use and thereby reduce adverse outcomes in patients with schizophrenia is of great public health importance. ..
- SERTRALINE FOR ALCOHOL DEPENDENCE AND DEPRESSIONHelen Pettinati; Fiscal Year: 2003..Overall, this project will determine if combining pharmacotherapies results in a better response in comorbidly depressed alcoholics than either medication alone or placebo. ..
- Cocaine Withdrawal and Pharmacotherapy ResponseMehmet Sofuoglu; Fiscal Year: 2007..This proposal, by testing the efficacy of carvedilol and investigating the influence of withdrawal severity on carvedilol's efficacy, may result in development of more effective treatments for cocaine addiction. ..
- Cannabis & Schizophrenia: fMRI Reward Circuit BiomakerAlan Green; Fiscal Year: 2005..Finding new medications, safer than CLOZ, that may be able to limit cannabis use In patients with SCHIZ is thus of considerable public health relevance. ..
- Three Methods for Costing Methadone Treatment ServicesGARY ZARKIN; Fiscal Year: 2006..abstract_text> ..
- Antipsychotics and Alcohol Drinking in RodentsAlan Green; Fiscal Year: 2005..The long-term goal of our research is to create better treatments for alcoholism in patients with SCH (and possibly even in those without SCH). ..
- TRAINING IN FUNCTIONAL IMAGING AND ALCOHOL WITHDRAWALDONALD MYRICK; Fiscal Year: 2004....
- Progestrone and the Effects of NicotineMehmet Sofuoglu; Fiscal Year: 2006..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
- Modeling Benefits and Costs of Prison-Based Substance Abuse TreatmentGARY ZARKIN; Fiscal Year: 2007..2005a). Results will help policy makers make better judgments about the allocation of funding to prison-based drug treatment resources. ..
- Modeling Benefits and Costs of Prison-Based Substance Abuse TreatmentGARY ZARKIN; Fiscal Year: 2009..2005a). Results will help policy makers make better judgments about the allocation of funding to prison-based drug treatment resources. ..
- GABA Medications for Tobacco AddictionMehmet Sofuoglu; Fiscal Year: 2009..The findings of this study will provide valuable information to develop new pharmacotherapies for smoking cessation. ..
- COST EFFECTIVENESS OF ALCOHOL TREATMENTGARY ZARKIN; Fiscal Year: 2004..abstract_text> ..